BAYN Stock Overview
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Bayer Aktiengesellschaft Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €28.08 |
52 Week High | €58.69 |
52 Week Low | €25.00 |
Beta | 0.97 |
1 Month Change | 2.20% |
3 Month Change | -2.01% |
1 Year Change | -51.86% |
3 Year Change | -48.26% |
5 Year Change | -50.27% |
Change since IPO | -77.20% |
Recent News & Updates
Recent updates
Shareholder Returns
BAYN | AT Pharmaceuticals | AT Market | |
---|---|---|---|
7D | 1.8% | -1.3% | 1.0% |
1Y | -51.9% | 5.9% | 4.6% |
Return vs Industry: BAYN underperformed the Austrian Pharmaceuticals industry which returned 5.9% over the past year.
Return vs Market: BAYN underperformed the Austrian Market which returned 4.6% over the past year.
Price Volatility
BAYN volatility | |
---|---|
BAYN Average Weekly Movement | 4.0% |
Pharmaceuticals Industry Average Movement | 5.2% |
Market Average Movement | 3.5% |
10% most volatile stocks in AT Market | 5.1% |
10% least volatile stocks in AT Market | 1.7% |
Stable Share Price: BAYN has not had significant price volatility in the past 3 months.
Volatility Over Time: BAYN's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1863 | 96,931 | Bill Anderson | www.bayer.com |
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
Bayer Aktiengesellschaft Fundamentals Summary
BAYN fundamental statistics | |
---|---|
Market cap | €27.53b |
Earnings (TTM) | -€2.94b |
Revenue (TTM) | €47.64b |
0.6x
P/S Ratio-9.4x
P/E RatioIs BAYN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BAYN income statement (TTM) | |
---|---|
Revenue | €47.64b |
Cost of Revenue | €19.75b |
Gross Profit | €27.89b |
Other Expenses | €30.83b |
Earnings | -€2.94b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
Earnings per share (EPS) | -2.99 |
Gross Margin | 58.55% |
Net Profit Margin | -6.17% |
Debt/Equity Ratio | 132.3% |
How did BAYN perform over the long term?
See historical performance and comparison